Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.
From the official U.S. FDA label for phenobarbital, the active ingredient registered with NAFDAC.
Sedative Anticonvulsant- For the treatment of generalized and partial seizures.
The following adverse reactions have been reported: CNS Depression- Residual sedation or "hangover," drowsiness, lethargy, and vertigo. Emotional disturbances and phobias may be accentuated. In some persons, barbiturates such as phenobarbital repeatedly produce excitement rather than depression, and the patient may appear to be inebriated. Irritability and hyperactivity can occur in children. Like other nonanalgesic hypnotic drugs, barbiturates such as phenobarbital, when given in the presence of pain, may cause restlessness, excitement, and even delirium. …
Phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident.
1. Habit-Forming Phenobarbital may be habit-forming. Tolerance and psychological and physical dependence may occur with continued use ( see Drug Abuse and Dependence and Pharmacokinetics under Clinical Pharmacology ). Patients who have psychologic dependence on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop a physical dependence on barbiturates. In order to minimize the possibility of overdosage or the development of dependence, the prescribing and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. …
3. Usage in Pregnancy Barbiturates can cause fetal damage when administered to a pregnant woman. Retrospective, case-controlled studies have suggested a connection between the maternal consumption of barbiturates and a higher than expected incidence of fetal abnormalities. Barbiturates readily cross the placental barrier and are distributed throughout fetal tissues; the highest concentrations are found in the placenta, fetal liver and brain. …
STORAGE Keep tightly closed. Store at controlled room temperature, 20°-25°C (68° -77°F). [See USP]
Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.
Bitalshin 100 mg/mL Injection contains Phenobarbital (100 mg/mL), as solution for injection, according to its NAFDAC registration record.
Yes. Bitalshin 100 mg/mL Injection is listed on the NAFDAC register under registration number A4-101140, and its registration is active as of 5 November 2026.
No WHO falsified or substandard medical product alert currently matches Bitalshin 100 mg/mL Injection in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number A4-101140, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Sedative Anticonvulsant- For the treatment of generalized and partial seizures. (Summarised from the official U.S. FDA label for phenobarbital. Always follow your doctor or pharmacist.)
Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.